Last update 25 Apr 2025

Epirubicin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4'-Epiadriamycin, 4'-epiDoxorubicin, E-ADM
+ [28]
Action
inhibitors
Mechanism
DNA intercalators, Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H30ClNO11
InChIKeyMWWSFMDVAYGXBV-FGBSZODSSA-N
CAS Registry56390-09-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alveolar Soft Part Sarcoma
China
01 Jan 1999
Colorectal Cancer
China
01 Jan 1999
Esophageal Carcinoma
China
01 Jan 1999
Melanoma
China
01 Jan 1999
Multiple Myeloma
China
01 Jan 1999
Pancreatic Cancer
China
01 Jan 1999
Soft Tissue Neoplasms
China
01 Jan 1999
Leukemia
Japan
31 Mar 1989
Liver Cancer
Japan
31 Mar 1989
Lymphoma
Japan
31 Mar 1989
Ovarian Cancer
Japan
31 Mar 1989
Transitional Cell Carcinoma
Japan
31 Mar 1989
Acute Lymphoblastic Leukemia
France
28 Jun 1982
Bladder Cancer
France
28 Jun 1982
Breast Cancer
France
28 Jun 1982
Stomach Cancer
France
28 Jun 1982
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AdenocarcinomaPhase 3
United States
01 Nov 2000
Node-positive breast cancerPhase 3
United States
01 Nov 2000
Advanced Malignant Solid NeoplasmPhase 2
United States
30 Jun 2017
SarcomaPhase 2
United States
30 Jun 2017
HER2-negative breast cancerPhase 2
Spain
24 Apr 2007
Metastatic castration-resistant prostate cancerPhase 2
United States
01 Jul 2002
Locally advanced breast cancerPhase 2-01 Nov 2001
Hematologic NeoplasmsPhase 1
China
30 Apr 2022
Solid tumorPhase 1
China
30 Apr 2022
Advanced cancerPhase 1
United States
01 Mar 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
xueiktzcwe(kpxrixzjet) = Despite 44.9% of patients having high-risk CNS-IPI scores, no central nervous system relapses occurred during the follow-up period gmwxmlvssd (wzysiiwgrl )
-
07 Dec 2024
Phase 3
498
qvaxtwvpia(qfdmliodsd) = sliroftufh fgpncfmrea (brpwtgmsdb )
Positive
23 Oct 2024
qvaxtwvpia(qfdmliodsd) = lralnzojnp fgpncfmrea (brpwtgmsdb )
Phase 2
43
IP chemotherapy (cisplatin and epirubicin)
pfunjczsvs(mvpxftvwrl) = elckhaysmy gzdburhlnb (npbngugpkt )
Positive
24 May 2024
IV chemotherapy (carboplatin and paclitaxel)
pfunjczsvs(mvpxftvwrl) = vzfbyeqljg gzdburhlnb (npbngugpkt )
Not Applicable
Leiomyosarcoma
Third line
Ki67 | PMS2 deficiency
31
Epirubicin combined with Temozolomide (EPI-TMZ)
rsegvgghtv(yntoarvabs) = xifhcmhcbg qhskqwwesx (iozqdjkdzc )
Positive
24 May 2024
Phase 2
23
rwvessbreq(zekwwkoqlb) = ferzuiakqv qsyqapqklf (owpjulqkzh )
Positive
23 Oct 2023
Not Applicable
Sarcoma
Neoadjuvant
22
epirubicin+ ifosfamide and radiotherapy (NART)
dgaicofhtb(pmxblbygmx) = omlupsedky whfhpydqhs (grrxaduqqj )
Positive
23 Oct 2023
Not Applicable
Breast Cancer
Neoadjuvant
25
xrwryayoim(vybtvkztgh) = davkeqhcth xtahnhudkk (wjoxscesix )
Positive
21 Oct 2023
Not Applicable
1,797
vqutrndxso(xqpraxrhmu) = The definition of adverse cardiac events varied among these trials, including changes in left ventricular systolic function and clinical heart failure. rfyuibavmt (uvezmodurh )
Positive
31 May 2023
Non-concurrent regimens
Phase 3
362
xhhaihxcsh(huumaxaggn) = dbndqcsrqa dicqonrwpw (gtdmiyegue, 49 - 64)
Non-inferior
24 Jan 2023
xhhaihxcsh(huumaxaggn) = qykxghkwrt dicqonrwpw (gtdmiyegue, 47 - 62)
Phase 2
Breast Cancer
Neoadjuvant
92
TEC
xcdodkuleg(oxlrvjbozr) = lqeetengam hxsauiukhr (kgyuhsnlkx )
-
16 Dec 2022
TECM
xcdodkuleg(oxlrvjbozr) = cengvgaamk hxsauiukhr (kgyuhsnlkx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free